Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1990 2
1991 2
1992 2
1996 4
1998 1
2000 1
2001 1
2002 1
2003 1
2004 2
2005 6
2006 9
2007 14
2008 16
2009 25
2010 34
2011 21
2012 25
2013 27
2014 29
2015 24
2016 29
2017 31
2018 33
2019 41
2020 46
2021 57
2022 35
2023 37
2024 30
2025 45
2026 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

575 results

Results by year

Filters applied: . Clear all
Page 1
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Meyer ML, Peters S, Borghaei H, Cascone T, Dacic S, Faivre-Finn C, Leighl N, Paz-Ares L, Aerts J, Aggarwal C, Ahn MJ, Arcila ME, Ardizzoni A, Arrieta O, Awad MM, Bar J, Barlesi F, Bazhenova L, Besse B, Chaft J, Cho BC, Curioni Fontecedro A, DE Ruysscher D, Dingemans AM, Dziadziuszko R, Felip E, Forde P, Gandara DR, Garassino MC, Garcia Campelo R, Garrido Lopez P, Gautschi O, Girard N, Goto Y, Gray J, Hendriks L, Hirsch F, Hui R, Janne PA, Kerr K, Khorshid O, Pechoux CLE, Leal T, Lin JJ, Linardou H, Liu S, Mahrous M, Malapelle U, Mercadante E, Mitsudomi T, Mok T, Mountzios G, Naidoo J, Normanno N, Novello S, Oliveira J, Pappagallo G, Perrone G, Pérol M, Raez LE, Ramella S, Rami-Porta R, Reckamp K, Reguart Aransay N, Remon Masip J, Ricardi U, Ricciuti B, Rodriguez-Abreu D, Rotow JK, Santos ES, Schalper K, Senan S, Seto T, Skoulidis F, Smit EF, Soares M, Solli P, Solomon B, Soo RA, Stahel R, Stiles BM, VAN Schil P, Veronesi G, Wistuba II, Wolf J, Wu YL, Zer A, Rolfo C, Landi L, Cappuzzo F. Meyer ML, et al. Among authors: de ruysscher d. J Thorac Oncol. 2026 Jul 30:104111. doi: 10.1016/j.jtho.2026.104111. Online ahead of print. J Thorac Oncol. 2026. PMID: 42532338 Free article.
Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose.
Greystoke A, Brown S, Chalmers A, Dean JA, Deutsch E, Dillon MT, Franks K, Forster MD, Hanna GG, Harrington K, Harrow S, Hiley C, Holmes J, Krebs MG, Kendall J, McAlister R, Minchom A, Myers R, Oughton J, Butterworth KT, De Ruysscher D, Shaw P, Vokes E, Walls GM, Faivre-Finn C. Greystoke A, et al. Among authors: de ruysscher d. Int J Radiat Oncol Biol Phys. 2026 Jul 30:S0360-3016(26)03921-0. doi: 10.1016/j.ijrobp.2026.06.3067. Online ahead of print. Int J Radiat Oncol Biol Phys. 2026. PMID: 42530498 Review.
Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.
Heumann P, Romero JCR, Aguado Barrera ME, Aguado Flor E, Avuzzi B, Azria D, Briers E, Carballo-Castro A, Chang-Claude J, Choudhury A, Dunning A, Elliott RM, Fachal L, Farcy-Jacquet MP, Gómez-Caamaño A, Gutiérrez-Enríquez S, Herskind C, Kaaks R, Kerns SL, Lambrecht M, Maldonado X, Michalet M, Chiorda BN, Peleteiro-Higueiro P, Rattay T, Rosenstein BS, De Ruysscher D, Sperk E, Stobart H, Symonds RP, Talbot CJ, Tubío-Abuín MA, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML; REQUITE/REQUITEplus/RADprecise consortia; Seibold P, Rancati T. Heumann P, et al. Among authors: de ruysscher d. Clin Transl Radiat Oncol. 2026 Jul 2;60:101219. doi: 10.1016/j.ctro.2026.101219. eCollection 2026 Sep. Clin Transl Radiat Oncol. 2026. PMID: 42500362 Free PMC article.
Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects.
Webb AJ, Harper E, Rattay T, Aguado-Barrera ME, Avuzzi B, Bultijnck R, Choudhury A, De Ruysscher DK, Fuentes-Ríos O, Gutiérrez-Enríquez S, Kerns SL, Lobato-Busto R, McWilliam A, Noris Chiorda B, Rancati T, Rosenstein BS, Seibold P, Sperk E, Vega A, Veldeman L, Ward TH, West CM, Symonds P, Talbot CJ. Webb AJ, et al. Among authors: de ruysscher dk. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0268. Online ahead of print. Clin Cancer Res. 2026. PMID: 42440347
Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.
Vaes RDW, Chen Z, Laven IEWG, Lyu S, Welbers TTJ, Piepers JAF, Hillen LM, von der Thüsen JH, Clarijs R, Decaudin D, Montaudon E, Blok MJ, Sprooten RTM, Hendriks LEL, Dursun S, Maessen JG, Degens JHRJ, Gronenschild MHM, Custers FLJ, de Loos ER, Dingemans AC, van Gent DC, Vooijs MA, De Ruysscher D. Vaes RDW, et al. Among authors: de ruysscher d. NPJ Precis Oncol. 2026 Jul 9. doi: 10.1038/s41698-026-01598-5. Online ahead of print. NPJ Precis Oncol. 2026. PMID: 42426227 Free article.
Associations between body composition and radiotherapy-related side-effects and health-related quality of life in patients with prostate or lung cancer: sub-analysis of the REQUITE trial.
Vickers AJ, McSweeney DM, Choudhury A, Weaver J, West C, Kerns S, Azria D, Farcy-Jaquet MP, Chang-Claude J, Dunning A, Lambrecht M, Avuzzi B, De Ruysscher D, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Bultijnck R, Webb A, Rosenstein B, Rancati T, Gioscio E, Price G, McWilliam A. Vickers AJ, et al. Among authors: de ruysscher d. Radiother Oncol. 2026 Jun 27;222:111673. doi: 10.1016/j.radonc.2026.111673. Online ahead of print. Radiother Oncol. 2026. PMID: 42364819
Charting the Biosynthetic Landscape of Hybrid Polyketide-Nonribosomal Peptide-Specialized Lipids.
El Arnouki Belhaji F, De Ruysscher D, Vanreppelen G, Huybrechts LL, Alanjary MM, Zdouc MM, de Los Santos ELC, Demaerel J, Vaneeckhaute E, Van Goethem O, Gerstmans H, Breynaert E, Van Dijck P, Medema MH, Weir ANM, Lescrinier E, Masschelein J. El Arnouki Belhaji F, et al. Among authors: de ruysscher d. JACS Au. 2026 Jun 8;6(6):3363-3375. doi: 10.1021/jacsau.6c00386. eCollection 2026 Jun 22. JACS Au. 2026. PMID: 42358726 Free PMC article.
Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma.
Ta BDP, Canters RAM, van der Klugt K, Vilches-Freixas G, Kneepkens E, Vereijken F, Cobben M, van den Bosch M, Lubken I, Stultiens C, Velders M, Verstappen T, Tholen G, Niezink AGH, De Ruysscher DKM, Berbée M. Ta BDP, et al. Among authors: de ruysscher dkm. Phys Imaging Radiat Oncol. 2026 May 10;39:100996. doi: 10.1016/j.phro.2026.100996. eCollection 2026 May. Phys Imaging Radiat Oncol. 2026. PMID: 42182961 Free PMC article.
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D. Peters S, et al. Among authors: de ruysscher d. Nat Cancer. 2026 Jul;7(7):1121-1132. doi: 10.1038/s43018-026-01161-y. Epub 2026 May 13. Nat Cancer. 2026. PMID: 42129521 Free PMC article. Clinical Trial.
575 results